[go: up one dir, main page]

DK3066108T3 - 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-beta-d-glucopyranosidacetat - Google Patents

4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-beta-d-glucopyranosidacetat Download PDF

Info

Publication number
DK3066108T3
DK3066108T3 DK14802974.7T DK14802974T DK3066108T3 DK 3066108 T3 DK3066108 T3 DK 3066108T3 DK 14802974 T DK14802974 T DK 14802974T DK 3066108 T3 DK3066108 T3 DK 3066108T3
Authority
DK
Denmark
Prior art keywords
glucopyranosidacetat
diazaspiro
undec
methylbenzyl
pyrazol
Prior art date
Application number
DK14802974.7T
Other languages
English (en)
Inventor
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK3066108T3 publication Critical patent/DK3066108T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK14802974.7T 2013-11-08 2014-10-30 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-beta-d-glucopyranosidacetat DK3066108T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361901488P 2013-11-08 2013-11-08
PCT/US2014/063161 WO2015069541A1 (en) 2013-11-08 2014-10-30 4-{4-[(1 e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1 -en-1 -yl]-2-methylbenzyl}-5-(propan-2-yl)-1 h-pyrazol-3-yl beta-d- glucopyranoside acetate

Publications (1)

Publication Number Publication Date
DK3066108T3 true DK3066108T3 (da) 2019-01-02

Family

ID=51982747

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14802974.7T DK3066108T3 (da) 2013-11-08 2014-10-30 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-beta-d-glucopyranosidacetat

Country Status (35)

Country Link
US (1) US9573970B2 (da)
EP (1) EP3066108B1 (da)
JP (1) JP6197113B2 (da)
KR (1) KR101858881B1 (da)
CN (1) CN105705509B (da)
AP (1) AP2016009180A0 (da)
AR (2) AR098670A1 (da)
AU (1) AU2014347065B2 (da)
CA (1) CA2925128C (da)
CL (1) CL2016000791A1 (da)
CR (1) CR20160165A (da)
CY (1) CY1121096T1 (da)
DK (1) DK3066108T3 (da)
DO (1) DOP2016000067A (da)
EA (1) EA028801B1 (da)
ES (1) ES2703944T3 (da)
HR (1) HRP20182061T1 (da)
IL (1) IL244899B (da)
JO (1) JO3485B1 (da)
LT (1) LT3066108T (da)
MA (1) MA39019A1 (da)
MX (1) MX368174B (da)
MY (1) MY192242A (da)
NZ (1) NZ718118A (da)
PE (1) PE20160884A1 (da)
PH (1) PH12016500851B1 (da)
PL (1) PL3066108T3 (da)
PT (1) PT3066108T (da)
RS (1) RS58050B1 (da)
SI (1) SI3066108T1 (da)
SV (1) SV2016005190A (da)
TN (1) TN2016000112A1 (da)
TW (1) TWI655198B (da)
UA (1) UA118767C2 (da)
WO (1) WO2015069541A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992726A1 (ru) * 2017-06-12 2020-04-23 Лингамед, Ллс Способ получения (s,s)-секоизоларицирезинола диглюкозида и (r,r)-секоизоларицирезинола диглюкозида
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
JP4141258B2 (ja) 2001-02-26 2008-08-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
WO2004014932A1 (ja) 2002-08-08 2004-02-19 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CN100351263C (zh) * 2002-08-08 2007-11-28 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7973012B2 (en) * 2006-05-19 2011-07-05 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound
JP5144683B2 (ja) 2007-12-27 2013-02-13 キッセイ薬品工業株式会社 ピラゾール誘導体のモノセバシン酸塩
MY155658A (en) 2009-02-23 2015-11-13 Taisho Pharmaceutical Co Ltd A-isopropylphenyl glucitol compounds as sglti inhibitors
US20120270819A1 (en) 2009-10-02 2012-10-25 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone disease
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
CA2925128C (en) 2017-10-17
MX2016005999A (es) 2016-07-22
HRP20182061T1 (hr) 2019-02-08
TWI655198B (zh) 2019-04-01
JP6197113B2 (ja) 2017-09-13
MY192242A (en) 2022-08-10
LT3066108T (lt) 2019-01-25
PH12016500851B1 (en) 2020-02-19
SV2016005190A (es) 2018-11-01
EP3066108B1 (en) 2018-10-24
EA201690749A1 (ru) 2016-08-31
MA39019A1 (fr) 2017-04-28
EP3066108A1 (en) 2016-09-14
SI3066108T1 (sl) 2018-12-31
IL244899B (en) 2019-10-31
KR20160067157A (ko) 2016-06-13
ES2703944T3 (es) 2019-03-13
US9573970B2 (en) 2017-02-21
PL3066108T3 (pl) 2019-03-29
IL244899A0 (en) 2016-05-31
CR20160165A (es) 2016-06-08
CY1121096T1 (el) 2019-12-11
PH12016500851A1 (en) 2016-06-20
CN105705509A (zh) 2016-06-22
AU2014347065A1 (en) 2016-04-07
TN2016000112A1 (en) 2017-07-05
AU2014347065B2 (en) 2016-09-29
TW201609783A (zh) 2016-03-16
JP2016539099A (ja) 2016-12-15
AR124083A2 (es) 2023-02-08
AP2016009180A0 (en) 2016-04-30
PT3066108T (pt) 2018-11-29
US20160215011A1 (en) 2016-07-28
CA2925128A1 (en) 2015-05-14
WO2015069541A1 (en) 2015-05-14
NZ718118A (en) 2017-11-24
DOP2016000067A (es) 2016-04-15
CN105705509B (zh) 2018-12-04
CL2016000791A1 (es) 2016-11-11
RS58050B1 (sr) 2019-02-28
MX368174B (es) 2019-09-23
PE20160884A1 (es) 2016-09-10
AR098670A1 (es) 2016-06-08
JO3485B1 (ar) 2020-07-05
UA118767C2 (uk) 2019-03-11
KR101858881B1 (ko) 2018-05-16
EA028801B1 (ru) 2017-12-29

Similar Documents

Publication Publication Date Title
DK3587417T3 (da) 1,3-thiazol-2-yl-substituerede benzamider
JP2015520632A5 (da)
BR112015001201A2 (pt) compostos anti-infecciosos 5,5-heteroaromáticos.
HUE040304T2 (hu) 2-Amino-6-(difluor-metil)-5,5-difluor-6-fenil-3,4,5,6-tetrahidropiridinek, mint bace1 inhibitorok
CL2015003007A1 (es) Carboxamidas fungicidas.
LT3593808T (lt) Protonus surišantys polimerai, skirti vartojimui per burną
BR112015021204A2 (pt) codificador, decodificador e método.
CL2015003006A1 (es) Amidas fungicidas.
BR112016009048A2 (pt) Composição de copolímero, processo para a produção do copolímero, e composição
FR3007636B1 (fr) Trocart perforant.
DK3402783T3 (da) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decan-derivater
ES2651188T8 (es) Composición líquida fotopolimerizable
BR112014032501A2 (pt) composto, e, composição farmacêutica.
FR3026399B1 (fr) Grue, notamment grue-derrick
HRP20180585T1 (hr) Spojevi 2,7-diazaspiro[3.5]nonana
DK3066108T3 (da) 4-{4-[(1e)-4-(2,9-diazaspiro[5.5]undec-2-yl)but-1-en-1-yl]-2-methylbenzyl}-5-(propan-2-yl)-1h-pyrazol-3-yl-beta-d-glucopyranosidacetat
JP2015521279A5 (da)
PT2906515T (pt) Material duro com baixa quantidade de aglutinante, resistente ao desgaste
JP2014189771A5 (da)
ES1079113Y (es) Estructura mejorada para palé de material moldeable.
TH1601002568A (th) 4-{4-[(1e)-4-(2,9-ไดอะซะสไพโร[5.5]อันเดค-2-อิล)บิวท์-1-เอ็น-1-อิล]-2- เมธิลเบนซิล}-5-(โพรแพน-2-อิล)-1h-ไพเเรซอล-3-อิล เบทา-d-กลูโคไพแรโนไซด์ แอซิเทท
FR3022568B1 (fr) Procede de construction d'un batiment, notamment a usage d'habitation a double coque, habitation obtenue
TH1401007610A (th) องค์ประกอบที่ประกอบด้วยสารออกฤทธิ์ทางชีวภาพ
TH1401007202A (th) จุลินทรีย์และวิธีการสำหรับผลิต 4-ไฮดรอกซีบิวทิเรต, 1,4-บิวเทนไดออลและสารประกอบที่เกี่ยวข้อง
BR302013003493S1 (pt) Configuração aplicada em estojo.